Document is current
Any future updates will be listed below
-
Authors
Püsküllüoğlu, Mirosława https://orcid.org/0000-0002-2647-9625
Pieniążek, Małgorzata
Rudzińska, Agnieszka
Pietruszka, Agnieszka
Pacholczak-Madej, Renata
Grela-Wojewoda, Aleksandra
Ziobro, Marek
- License Information
-
More Information
Article History
Received: 31 March 2024
Accepted: 1 May 2024
First Online: 4 June 2024
Declarations
:
: The authors declare that they have no competing interests that could influence this study. Authors declare travel grants or lecture fees: Mirosława Püsküllüoğlu from Gilead, AstraZeneca, Novartis, Roche, Amgen and Janssen; Małgorzata Pieniążek Pfizer from Novartis, Gilead; Agnieszka Rudzińska from Sandoz; Agnieszka Pietruszka from Novartis, MSD, Merck; Renata Pacholczak-Madej from GSK, Accord, BMS; Aleksandra Grela-Wojewoda from Novartis, BMS, Pierre Fabre, Roche, Amgen, MSD, Gilead, Pfizer; Marek Ziobro from Pierre Fabre, Novartis, Ipsen.
: The Ethical Committee of the Maria Sklodowska-Curie National Research Institute of Oncology Branch Krakow granted ethical approval, as indicated by decision number 1/2023 dated 18 April 2023. In accordance with the Ethical Committee's decision, written informed consent was not mandatory due to the retrospective nature of the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional Ethical Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
